Article Text
Statistics from Altmetric.com
The papers brought together in this supplement of the Annals of the Rheumatic Diseases constitute summaries of presentations at the XIIIth International Symposium on Advances in Targeted Therapies, which was held from 6 to 9 April 2011. These presentations represent the state of the art on the biology of mechanisms of action and pathophysiology of tumour necrosis factor (TNF) and other important mediators of inflammation. Current knowledge on the means and consequences of blocking TNF or other molecules or cellular mechanisms is also presented.
We are grateful to Drs Crofford, Feldmann, …
Footnotes
-
Funding The following companies provided unrestricted educational grants for the organisation of this conference: Abbott, Amgen, Bristol-Myers Squibb, Mitsubishi Tanabe, Pfizer, Roche, Savient Pharmaceuticals and UCB. The pharmaceutical industry had no part in the decisions about the specific programme and, with the exception of a few observers, participants were selected and invited solely by the organising committee.
-
Competing interests Several members of the advisory board and the members of the organising committee obtained experience in the use of biological compounds during their participation in clinical studies on these agents (for which the costs were defrayed by industry).
-
Provenance and peer review Commissioned; internally peer reviewed.